Literature DB >> 29045197

Triple Therapy for Atrial Fibrillation after PCI.

Jonathan P Piccini1, W Schuyler Jones1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29045197     DOI： 10.1056/NEJMe1710753

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach.

Authors:  Sagar Dugani; Jeffrey M Ames; JoAnn E Manson; Samia Mora
Journal:  Curr Atheroscler Rep       Date:  2018-02-21       Impact factor: 5.113

Review 2.  Ticagrelor or prasugrel vs. clopidogrel in combination with anticoagulation for treatment of acute coronary syndrome in patients with atrial fibrillation.

Authors:  Irene Kirolos; Ikechukwu Ifedili; Miguel Maturana; Alykhan Moez Premji; Brandon Cave; Sherif Roman; David Jones; Romany Gaid; Yehoshua C Levine; Sunil Jha; Rajesh Kabra; Rami N Khouzam
Journal:  Ann Transl Med       Date:  2019-09

Review 3.  Triple Therapy: When, if Ever?

Authors:  Nino Mihatov; Eric A Secemsky; Sammy Elmariah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-07-03

4.  Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal.

Authors:  Mattia Galli; Felicita Andreotti; Domenico D'Amario; Rocco Vergallo; Rocco A Montone; Giampaolo Niccoli; Filippo Crea
Journal:  Int J Cardiol Heart Vasc       Date:  2020-05-14

5.  When to withhold oral anticoagulation in atrial fibrillation - an overview of frequent clinical discussion topics.

Authors:  Jaap Seelig; Ron Pisters; Martin E Hemels; Menno V Huisman; Hugo Ten Cate; Marco Alings
Journal:  Vasc Health Risk Manag       Date:  2019-09-17

Review 6.  Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.

Authors:  Leonardo De Luca; Raffaella Mistrulli; Francesco Antonio Veneziano; Francesco Grigioni; Massimo Volpe; Francesco Musumeci; Domenico Gabrielli
Journal:  J Clin Med       Date:  2022-01-20       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.